- 中文名称
Anti-Human VEGFR-2/KDR, Antagonistic
- 英文名字
- Anti-Human VEGFR-2/KDR, Antagonistic
- 供应商
- ReliaTech
- 产品货号
- mV1001.1m-h
- 产品报价
- ￥询价/200ug
- 产品说明书
- 点击查看
- 购买方式
- 90%产品中国有现货库存。银行转账、电汇、支票、现金，在线支付宝及网银支付，或直接与我们电话联系400-6800-868
- 产品新闻
- 背景资料
- VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands.
- 应用类型
- WB, Attenuation of VEGF-induced KDR tyrosine phosphorylation
- 免疫原
- 该Anti-Human VEGFR-2/KDR, Antagonistic的详细信息查看ReliaTech提供的产品说明书。
- 来源宿主
- 该Anti-Human VEGFR-2/KDR, Antagonistic的详细信息查看ReliaTech提供的产品说明书。
- 反应性
- 该Anti-Human VEGFR-2/KDR, Antagonistic的详细信息查看ReliaTech提供的产品说明书。
- 保存建议
- 该Anti-Human VEGFR-2/KDR, Antagonistic的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute the antibody with 400 µl sterile PBS and the final concentration is 500 µg/ml.
- 其他
- ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。
- 注意
-
该页面的中文产品信息的翻译，仅供参考。准确的产品信息请以厂家的英文说明书为准。下单前，请浏览说明书确认。
-
